Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis

Leuk Lymphoma. 2016 May;57(5):1215-8. doi: 10.3109/10428194.2015.1079320. Epub 2015 Oct 5.

Authors

Giovanni Caocci¹, Antonio Maccioni², Francesca Murgia¹, Alessandra Perra¹, Monica Usai¹, Michela Piga², Roberto Mascia², Giorgio La Nasa¹

Affiliations

¹ a Hematology Unit, Department of Medical Sciences , Bone Marrow Transplant Center, R. Binaghi Hospital, University of Cagliari , Cagliari , Italy and.
² b Pathology Unit , SS. Trinità Hospital, ASL 8 , Cagliari , Italy.

PMID: 26308187
DOI: 10.3109/10428194.2015.1079320

No abstract available

Publication types

Letter

MeSH terms

Bone Marrow / metabolism
Bone Marrow / pathology*
Cellular Microenvironment / drug effects*
Humans
Janus Kinases / antagonists & inhibitors
Janus Kinases / genetics
Mutation
Nitriles
Primary Myelofibrosis / drug therapy*
Primary Myelofibrosis / genetics
Primary Myelofibrosis / pathology*
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use*
Pyrazoles / pharmacology
Pyrazoles / therapeutic use*
Pyrimidines
Treatment Outcome

Substances

Nitriles
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
ruxolitinib
Janus Kinases